The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug price negotiation program under President Donald Trump's administration. The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that go into effect in 2027.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations for 10 drugs whose lower prices take effect in 2026. T

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — a move applauded by experts as they await the impact of the first-round of discounts anticipated next year.

The Centers for Medicare and Medicaid Services (CMS) has included Ozempic among the next 15 drugs chosen for Medicare negotiation. The CMS listed Ozempic, Rybelsus and Wegovy — all forms of

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under President Donald Trump's administration following criticism from the pharmaceutical industry for the Biden-era law.

CMS said it is considering ways to bring "greater transparency" to the Medicare drug pricing negotiation program mandated under the Inflation Reduction Act of 2022.